TC
RETA

TwinBeech Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

TwinBeech Capital’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,765
Closed -$910K – 774
2022
Q1 		$910K Sell
27,765
-17,438
-39% -$517K 0.04% 332
2021
Q4 		$1.19M Buy
+45,203
New +$3.5M 0.07% 313
2020
Q2 		– Sell
-6,053
Closed -$874K – 517
2020
Q1 		$874K Buy
+6,053
New +$1.17M 0.35% 101

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TwinBeech Capital's RETA Position: Q2 2022 in Review

TwinBeech Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2022, closing a stake of 27,765 shares — an estimated $910K sold.

TwinBeech Capital first reported a position in RETA in Q1 2020 and held it in 3 quarters. The position peaked at $1.19M in Q4 2021. 146 funds tracked by Wall St. Rank hold RETA as of Q2 2022.

  • TwinBeech Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • TwinBeech Capital sold 27,765 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2022, an estimated $910K.
  • TwinBeech Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 3 quarters.
  • TwinBeech Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.19M in Q4 2021.
  • 146 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2022.

Based on TwinBeech Capital's 13F filing for Q2 2022, filed 15 Aug 2022.